PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 3, 2026Annals of Medicine0 citationsOpen Access

Omission of clinical target volume in radiotherapy for unresectable stage III non-small cell lung cancer: a propensity score matching analysis

View Full Paper
WDWenxin DingJLJing LiangCCChaoying Chen

Key Points

  • This study aims to evaluate the impact of omitting clinical target volume on survival and adverse effects in patients with unresectable stage III NSCLC undergoing radiotherapy.
  • Conducted a cohort analysis of patients with unresectable stage III NSCLC receiving radiation therapy.
  • Performed propensity score matching to align groups and control for confounding variables.
  • Compared survival outcomes and incidence of grade ≥2 radiation pneumonitis between groups with and without CTV.
  • No statistically significant difference in survival was found by omitting the clinical target volume.
  • Omission of the CTV may lead to a reduction in the incidence of grade ≥2 radiation pneumonitis.

Abstract

In this cohort study of patients with unresectable stage III non-small cell lung carcinoma (NSCLC) undergoing radiation therapy, no statistically significant difference in survival was observed with omission of the CTV. However, omitting the CTV could reduce the incidence of grade ≥2 radiation pneumonitis, thereby alleviating the adverse reactions associated with this condition.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Ding et al. (2026) studied this question.

synapsesocial.com/papers/69cf59635a333a821460a0b7https://doi.org/10.1080/07853890.2026.2650866
Ask AI
Helpful
Bookmark
Share
View Full Paper